Exhibit 10.26 [REDACTED COPY]* DISTRIBUTION AGREEMENT Dated as of November 24, 1998Distribution Agreement • February 13th, 1998 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New Jersey
CONSULTING AGREEMENT CONSULTING AGREEMENT, dated as of December 16, 1996, between IMMUNOMEDICS, INC., a Delaware corporation having its principal executive office at 300 American Road, Morris Plains, New Jersey 07950 (the "Company"), and ROLF H. HENEL...Consulting Agreement • February 14th, 1997 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New Jersey
December 16, 1999 WARRANT AGREEMENT THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD,...Warrant Agreement • January 11th, 2000 • Immunomedics Inc • In vitro & in vivo diagnostic substances • California
SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of December 9, 1998, by and among Immunomedics, Inc., a Delaware corporation, with headquarters located at 300 American Road, Morris Plains, New Jersey 07950 (the...Securities Purchase Agreement • December 15th, 1998 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
OFOperating Agreement • March 24th, 1999 • Immunomedics Inc • In vitro & in vivo diagnostic substances
LICENSE AGREEMENT THIS LICENSE AGREEMENT (the "Agreement") is effective as of March 5, 1999 (the "Effective Date"), between IMMUNOMEDICS, INC. (hereinafter, Immunomedics"), having its principal place of business at 300 American Road, Morris Plains,...License Agreement • March 24th, 1999 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New Jersey
EXHIBIT 10.1 TERMINATION AGREEMENT(1) This Termination Agreement ("this Agreement"), dated as of this 7th day of April 2004 (the "Termination Effective Date"), is by and between IMMUNOMEDICS, INC., a Delaware corporation having its principal place of...Termination Agreement • May 13th, 2004 • Immunomedics Inc • In vitro & in vivo diagnostic substances • California
IMMUNOMEDICS, INC. 14,285,715 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 9th, 2019 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
Exhibit 1.1 ----------- JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G/A, dated February 14, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, par value $0.01 per share, of Immunomedics, Inc....Joint Filing Agreement • February 14th, 2003 • Immunomedics Inc • In vitro & in vivo diagnostic substances
The undersigned hereby agree that the Statement on this Schedule 13G/A, dated February 14, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, par value $0.01 per share, of Immunomedics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of December, 9, 1998, by and among Immunomedics, Inc., a Delaware corporation, with headquarters located at 300 American Road, Morris Plains, New Jersey 07950...Registration Rights Agreement • December 15th, 1998 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
Immunomedics, Inc. 300 American Road Morris Plains, NJ 07950 973-605-8200 January 7, 2000 The Aries Master Fund The Aries Domestic Fund, L.P. The Aries Domestic Fund II, L.P. Lindsay A. Rosenwald, M.D. Mark C. Rogers, M.D. Wayne Rothbaum c/o Paramount...Common Stock Purchase Agreement • January 11th, 2000 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
RIGHTS AGREEMENT Dated as of January 23, 1998 IMMUNOMEDICS, INC. and AMERICAN STOCK TRANSFER AND TRUST COMPANY Rights Agent TABLE OF CONTENTSRights Agreement • January 29th, 1998 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
July 28, 2004 CONFIDENTIAL ------------ Cynthia L. Sullivan President and Chief Executive Officer Immunomedics, Inc. 300 American Road Morris Plains, NJ 07950 Dear Cindy: The purpose of this letter agreement (the "Agreement") is to set forth the terms...Placement Agent Agreement • August 2nd, 2004 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
REDACTEDManufacturing Agreement • February 5th, 1997 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the "Agreement") is entered into this 31st day of December, 2006 (the "Effective Date") by and between Immunomedics, Inc., a Delaware corporation...Employment Agreement • January 3rd, 2007 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New Jersey
IMMUNOMEDICS, INC. SALES AGREEMENTSales Agreement • March 29th, 2019 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
Immunomedics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
CONSULTING AGREEMENTConsulting Agreement • September 29th, 1997 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
Exhibit 4.1 Immunomedics, Inc. 5% Senior Convertible Notes due 2008 & Common Stock Registration Rights AgreementRegistration Rights Agreement • May 2nd, 2005 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
RECITALWaiver Agreement • November 9th, 1999 • Immunomedics Inc • In vitro & in vivo diagnostic substances
ARTICLE III Covenants 3.1 Regulation S. (a) The Company shall take all necessary reasonable corporate action and proceedings as may be required by applicable law, rule or regulation for the legal and valid issuance of the Shares to the Purchasers at...Convertible Preferred Stock Purchase Agreement • November 14th, 1995 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
4,848,485 SHARES OF COMMON STOCK of IMMUNOMEDICS, INC. PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • May 2nd, 2007 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
EXHIBIT 4.3 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD OR OFFERED FOR SALE EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT...Common Stock Purchase Warrant • January 20th, 1998 • Immunomedics Inc • In vitro & in vivo diagnostic substances
FORM OF STOCK PURCHASE AGREEMENTStock Purchase Agreement • August 2nd, 2004 • Immunomedics Inc • In vitro & in vivo diagnostic substances
FORM OF DEPOSIT AGREEMENT IMMUNOMEDICS, INC. and as Depositary and HOLDERS OF DEPOSITARY RECEIPTSDeposit Agreement • April 23rd, 2004 • Immunomedics Inc • In vitro & in vivo diagnostic substances • Delaware
DEPOSIT AGREEMENT, dated as of , , by and among Immunomedics, Inc., a Delaware corporation (the “Company”), [ ], a [ ], as depositary (the “Depositary”), and all holders from time to time of Receipts issued hereunder.
AGREEMENT AND PLAN OF MERGER among: IMMUNOMEDICS, INC., a Delaware corporation; GILEAD SCIENCES, INC., a Delaware corporation; and MAUI MERGER SUB, INC., a Delaware corporation Dated as of September 13, 2020Merger Agreement • September 14th, 2020 • Immunomedics Inc • In vitro & in vivo diagnostic substances • Delaware
THIS AGREEMENT AND PLAN OF MERGER (“Agreement”) is made and entered into as of September 13, 2020, by and among: Gilead Sciences, Inc., a Delaware corporation (“Parent”); Maui Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”); and Immunomedics, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
Exhibit 10.1 IMMUNOMEDICS, INC. 5% Senior Convertible Notes Due 2008 PURCHASE AGREEMENT ------------------ April 27, 2005 IMMUNOMEDICS, INC., a Delaware corporation (the "Company"), hereby confirms its agreement with _______________ (the "Purchaser")...Purchase Agreement • May 2nd, 2005 • Immunomedics Inc • In vitro & in vivo diagnostic substances
IMMUNOMEDICS, INC. 9,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 2nd, 2014 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
Exhibit 4.2 COMMON STOCK WARRANT AGREEMENT dated as of April 29, 2005Common Stock Warrant Agreement • May 2nd, 2005 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
Form of Exchange AgreementExchange Agreement • November 7th, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
This Exchange Agreement and the Terms and Conditions for Exchange of Securities, dated October 2, 2018, attached hereto as Exhibit A (the “Terms and Conditions” and, together with this Exchange Agreement, the “Agreement”) is made as of the date hereof between the Company and the Investor.
IMMUNOMEDICS, INC. FORM OF UNDERWRITING AGREEMENT [DATE]Underwriting Agreement • April 23rd, 2004 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
Immunomedics, Inc., a corporation organized and existing under the laws of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of (i) [ ] shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), (b) [ ] shares of the Company’s preferred stock, par value $0.01 per share (the “Preferred Stock”), (c) [ ] depositary shares evidencing interests in a share or shares of Preferred Stock (“Depositary Shares”), (d) [ ] warrants to purchase Common Stock (“Common Stock Warrants”), or (e) [ ] warrants to purchase Preferred Stock (“Preferred Stock Warrants”), or any combination of such shares of Common Stock, shares of Preferred Stock, Depositary Shares, Common Stock Warrants and Preferred Stock Warrants (such securities or combination of securities to be sold to the Underwriters, the “Securities”). The Securities are more fully de
6,086,956 Shares IMMUNOMEDICS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 22nd, 2013 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
Immunomedics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 6,086,956 shares (the “Firm Shares”) of the Company’s common stock, $0.01 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 913,044 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”
INDEMNIFICATION AGREEMENTIndemnification Agreement • December 6th, 2017 • Immunomedics Inc • In vitro & in vivo diagnostic substances • Delaware
This Indemnification Agreement (this “Agreement”) is made as of , 20 , by and between Immunomedics, Inc., a Delaware corporation (the “Corporation”), and (“Indemnitee”). Capitalized terms used, but not otherwise defined herein, shall have the meanings set forth in Section 1.
Immunomedics, Inc.Registration Rights Agreement • April 23rd, 2004 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
Immunomedics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the purchaser named in the purchase agreement (the “Initial Purchaser”), upon the terms set forth in such purchase agreement dated January 12, 2004 (the “Purchase Agreement”), its 3.25% Convertible Senior Notes due 2006 (the “Securities”). As an inducement to the Initial Purchaser to enter into the Purchase Agreement and in satisfaction of a condition to the obligations of the Initial Purchaser thereunder, the Company agrees with the Initial Purchaser for the benefit of Holders (as defined herein) from time to time of the Registrable Securities (as defined herein) as follows:
DEVELOPMENT AND LICENSE AGREEMENT AS AMENDED AS OF APRIL 1, 2001Development and License Agreement • June 29th, 2001 • Immunomedics Inc • In vitro & in vivo diagnostic substances • Delaware
IMMUNOMEDICS, INC. 11,500,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 15th, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
